Scientists have discovered a natural compound produced by gut bacteria when they break down certain foods like pomegranates, walnuts, and berries. This compound, called urolithin A (UroA), may help repair and protect the lining of the intestines. The research, led by scientists at the University of Louisville, highlights a possible new way to treat inflammatory bowel disease (IBD), which includes conditions such as Crohn’s disease and ulcerative colitis. IBD is a group of disorders that cause chronic inflammation in the digestive tract, leading to symptoms like abdominal pain, diarrhea, and fatigue. The study focuses on how UroA interacts with a protein called the aryl hydrocarbon receptor (AHR). AHR acts like a sensor in the body, responding to signals from the environment, diet, and gut microbes. Earlier research had shown that certain beneficial dietary compounds can activate AHR in ways that support intestinal health, but the exact mechanisms were unclear. The new findings suggest that the effectiveness of this activation depends on both where it happens in the body and how strong the activation is. The researchers found that UroA specifically activates AHR in the cells that line the intestines, triggering a cellular defense system known as the NLRP6 inflammasome. While inflammasomes are often linked to harmful inflammation, the study shows that they can also be protective under certain conditions. When UroA activated the NLRP6 inflammasome in intestinal cells, it led to the release of molecules that help repair the gut lining, strengthen the intestinal barrier, increase the production of protective mucus, and improve the body's ability to fight harmful microbes—without causing more inflammation. To confirm their findings, the researchers used various methods, including cell studies, organoid models (miniature versions of human organs grown in the lab), and tissue samples from people with IBD. In the human tissue samples, UroA activated the same protective pathway seen in the other experiments. These results suggest that future treatments for IBD and other gastrointestinal diseases might target specific protective pathways in certain cells, rather than broadly suppressing the immune system. This could lead to more effective and less harmful therapies for people living with these conditions.